Info

Avigen, Inc. is a biopharmaceutical company engaged in developing and commercializing small molecule therapeutics to treat neurological and neuromuscular disorders. The Company’s lead product candidates primarily address spasticity, and neuromuscular spasm and neuropathic pain. Each of its two programs: AV650 and AV411, are commercially approved pharmaceuticals outside the United States. AV650 is an orally administered, centrally-acting small molecule known as tolperisone. AV411 is being developed as a first-in-class, non-opiate oral therapy for the treatment of neuropathic pain. AV513 is being developed as an oral therapy for the treatment of bleeding disorders. The Company maintains an ongoing preclinical research effort to identify additional opportunities to expand its product development pipeline.(Source: 10-K)